Study shows low dose aspirin reduces COVID-19’s patients’ risks of ICU admittance or death about 44% or more


COVID-19 is a new infectious disease which hit the world in 2020 or late 2019 and is the subject for several studies as scientists grapple with its novelty. A new study has shown that aspirin can reduce the risk of patient’s deaths as well as their admittance to the ICU.


The researchers from George Washington University School of Medicine, who led the study, said their findings show that aspirin is a fast, cheap and easy alternative when compared with other medications. Many coronavirus patients had thrombotic complications and blood clots formed in their bodies. So, they decided to use aspirin as it is a commonly recognized blood thinner.


The team published the study in the Anesthesia & Analgesia journal. The results showed that 44% of the patients who took aspirin had decreased chances of needing a ventilator and 43% were less likely to take a trip to the ICU. There was also a 47% decrease in the death rates of those patients who took aspirin.


So, the authors of the study concluded that patients who took aspirin may have improved outcomes as far as hospitalizations and deaths were considered, when compared with those who did not take the drug. However, there said that there is a necessity for large trials with aspirin.


This is not the first instance where aspirin has proved its efficacy. Another study found that more than  30,000 veterans who had been infected with the coronavirus and had been given aspirin due to pre-existing conditions had an up to 50% decrease in death at 30 days though the researchers said that more data was required for a firm conclusion.


Aspirin is used to treat a wide variety of aches and pains. It is used to relieve headaches, colds, and arthritis as well as muscle injuries. Take an aspirin is a common refrain. It is also used as an anti-platelet agent to minimize the risk of heart attacks and strokes. Its blood thinning properties make it a possible treatment for decreasing COVID-19 hospitalizations and deaths.


Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer